SINGAPORE (The Straits Times/ANN): The final phase of the clinical trial for a Covid-19 antibody developed by Singapore biotechnology company Tychan began on Friday (Dec 11).
The antibody can potentially help patients with the coronavirus to recover faster, while slowing the progression of the infection.
Already a subscriber? Log in
Get 20% OFF The Star Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
